Table 2.
Baseline Characteristics in Female Patients With FPLD Caused by LMNA vs PPARG Pathogenic Variants
| Clinical Parameters | PPARG Variant Group (n = 7) | LMNA Variant Group (n = 22) | P Value |
|---|---|---|---|
| Demographic and Anthropometric Parameters | |||
| Age, y | 30.8 ± 12.1 | 37.3 ± 15.2 | 0.3 |
| Height, cm | 161 ± 9 | 164 ± 8 | 0.4 |
| Weight, kg | 64 ± 13 | 70 ± 13 | 0.3 |
| BMI, kg/m2 | 24.4 ± 2.2 | 25.7 ± 3.4 | 0.3 |
| Systolic blood pressure, mm Hg | 124 ± 14 | 124 ± 16 | 0.9 |
| Diastolic blood pressure, mm Hg | 74 ± 9 | 73 ± 11 | 0.9 |
| Left arm fat, % | 24.5 ± 8.3 | 21.3 ± 5.4 | 0.3 |
| Right arm fat, % | 24.9 ± 7.1 | 21.8 ± 5.5 | 0.3 |
| Trunk fat, % | 27.2 ± 7.0 | 27.8 ± 6.4 | 0.9 |
| Left leg fat, % | 20.0 ± 5.5 | 17.7 ± 3.7 | 0.2 |
| Right leg fat, % | 19.2 ± 4.9 | 18.2 ± 4.1 | 0.6 |
| Subtotal fat, %a | 22.0 [19.5, 26.5] | 26.8 [22.6, 28.2] | 0.1 |
| Head fat, % | 24.4 ± 0.6 | 24.1 ± 1.9 | 0.8 |
| Total fat, % | 24.6 ± 5.6 | 23.8 ± 5.0 | 0.7 |
| Serum leptin, ng/mL | 6.3 ± 3.8 | 5.5 ± 2.5 | 0.5 |
| Glycemic Parameters | |||
|---|---|---|---|
| Fasting glucose, mg/dL | 177 ± 97 | 180 ± 89 | 0.9 |
| Fasting insulin, µU/mLa | 70 [27, 144] | 15 [11, 42] | 0.06 |
| C-peptide, ng/mLa | 3.7 [0.9, 5.2] | 4.1 [3.2, 4.9] | 0.5 |
| Hemoglobin A1c, % | 9.2 ± 2.3 | 7.8 ± 2.1 | 0.1 |
| AUC glucose, mg/dL/190 min | 62,883 ± 21,340 | 47,423 ± 15,610 | 0.05 |
| AUC insulin, µU/mL/190 mina | 9542 [4675, 23,805] | 14,505 [5429, 30,745] | 0.5 |
| AUC C-peptide, ng/mL/190 mina | 1436 [572, 1491] | 1525 [1122, 2823] | 0.045 |
| Metformin dose, mg/d | 2558 ± 685 | 1705 ± 467 | 0.008 |
| Insulin dose, U/kg/da | 3.8 [2.7, 4.3] | 1.7 [1.3, 4.4] | 0.3 |
| Number of diabetic medications | 2.6 ± 0.8 | 1.6 ± 0.9 | 0.02 |
| Lipid Parameters | |||
|---|---|---|---|
| Total cholesterol, mg/dLa | 321 [155, 415] | 205 [153, 243] | 0.4 |
| Triglycerides, mg/dLa | 1377 [278, 5577] | 332 [198, 562] | 0.06 |
| HDL-C, mg/dL | 27 ± 5 | 34 ± 10 | 0.3 |
| LDL-C, mg/dL | 60 ± 14 | 98 ± 31 | 0.06 |
| Number of lipid-lowering medications | 1.9 ± 0.7 | 1.1 ± 0.8 | 0.037 |
| Hepatic Parameters | |||
|---|---|---|---|
| Alanine aminotransferase, U/La | 36 [20, 46] | 29 [23, 47] | 0.8 |
| Aspartate aminotransferase, U/La | 25 [18, 37] | 25 [19, 30] | 0.8 |
Data are presented as mean ± SD. P < 0.05 is considered statistically significant.
Abbreviations: AUC, area under the curve; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
a
Represents data as median [25th percentile, 75th percentile].